Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
← catalyst calendarNCT07201558 · readout in 678 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48estimated
Sites
34
Countries
Australia, Belgium, Brazil +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-02 | actual | When the study began enrolling |
| Primary completion | 2028-06-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-27 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
Intervention
- Biological: Surovatamig
Primary outcomes
what the primary-completion date above is the date OFSafety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)
measured Day 1 to end of the study (up to 52 weeks)
Safety evaluation of surovatamig: Frequency of dose limiting toxicities (DLTs).
measured Day 1 to end of the study (up to 52 weeks)
Safety of surovatamig: Incidence of AEs/SAEs leading to discontinuation of surovatamig
measured Day 1 to end of the study (up to 52 weeks)
Tolerability of surovatamig: Incidence of treatment-related vital signs abnormalities
measured Day 1 to end of the study (up to 52 weeks)
Tolerability of surovatamig: Incidence of treatment-related clinical laboratory abnormalities
measured Day 1 to end of the study (up to 52 weeks)
Tolerability of surovatamig: Number of participants with abnormal ECG
measured From baseline through Day 180.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed